NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Orbimed Advisors Llc sold 24,609 shares of the firm's stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $14.05, for a total value of $345,756.45. Following the completion of the sale, the insider now directly owns 3,459,113 shares in the company, valued at $48,600,537.65. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Orbimed Advisors Llc also recently made the following trade(s):
- On Thursday, April 18th, Orbimed Advisors Llc sold 2,623 shares of NeuroPace stock. The stock was sold at an average price of $14.06, for a total value of $36,879.38.
- On Tuesday, April 16th, Orbimed Advisors Llc sold 14,069 shares of NeuroPace stock. The stock was sold at an average price of $14.01, for a total value of $197,106.69.
- On Thursday, April 11th, Orbimed Advisors Llc sold 461,899 shares of NeuroPace stock. The stock was sold at an average price of $14.49, for a total value of $6,692,916.51.
NeuroPace Stock Performance
Shares of NASDAQ:NPCE opened at $14.01 on Wednesday. The company has a market cap of $368.18 million, a P/E ratio of -10.95 and a beta of 2.09. The company has a debt-to-equity ratio of 2.76, a quick ratio of 5.02 and a current ratio of 5.71. NeuroPace, Inc. has a one year low of $3.80 and a one year high of $18.15. The business's 50-day simple moving average is $14.41 and its 200 day simple moving average is $11.52.
Claim Your Complimentary Bitcoin Reward
From Crypto Swap Profits | Ad
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you?
In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants.
Absolutely no strings attached.
Secure Your Spot Now
NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its quarterly earnings data on Tuesday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.10. NeuroPace had a negative return on equity of 153.76% and a negative net margin of 50.38%. The company had revenue of $18.01 million for the quarter, compared to the consensus estimate of $17.74 million. On average, sell-side analysts forecast that NeuroPace, Inc. will post -1.14 earnings per share for the current fiscal year.
Institutional Investors Weigh In On NeuroPace
Several hedge funds and other institutional investors have recently bought and sold shares of NPCE. Kent Lake Capital LLC increased its holdings in NeuroPace by 285.0% during the 3rd quarter. Kent Lake Capital LLC now owns 574,417 shares of the company's stock worth $5,589,000 after purchasing an additional 425,212 shares during the last quarter. EAM Investors LLC purchased a new stake in NeuroPace during the 3rd quarter worth approximately $1,378,000. Barclays PLC increased its holdings in NeuroPace by 9,085.6% during the 3rd quarter. Barclays PLC now owns 10,839 shares of the company's stock worth $105,000 after purchasing an additional 10,721 shares during the last quarter. Finally, Citigroup Inc. purchased a new stake in NeuroPace during the 3rd quarter worth approximately $29,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
NPCE has been the topic of a number of research reports. Leerink Partnrs restated an "outperform" rating on shares of NeuroPace in a report on Tuesday, January 30th. Wells Fargo & Company upgraded NeuroPace from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $16.00 to $20.00 in a report on Thursday, March 14th. SVB Leerink initiated coverage on NeuroPace in a report on Tuesday, January 30th. They issued an "outperform" rating and a $22.00 price objective on the stock. Lake Street Capital restated a "buy" rating and issued a $12.00 price objective on shares of NeuroPace in a report on Wednesday, December 27th. Finally, Cantor Fitzgerald raised their target price on NeuroPace from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, March 6th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $15.67.
View Our Latest Stock Analysis on NPCE
About NeuroPace
(
Get Free Report)
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
